Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03270956 · ClinicalTrials.gov registry record · Phase 2
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
A Phase 2 study, sponsored by Prokidney.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03270956 is a Phase 2 study that has completed, run by Prokidney. The registered enrollment target is 10 participants.
The verdict
NCT03270956, a Phase 2 study, has completed, sponsored by Prokidney.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-04-25 |
| Est. Completion | 2022-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03270956
The ClinicalTrials.gov registry entry for NCT03270956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT03270956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03270956 about?
NCT03270956 is a clinical study titled "A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease". The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
What is the current status of trial NCT03270956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-04-25. Estimated completion is 2022-11-17.
What interventions are being tested in trial NCT03270956?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03270956?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.